Operator: Ladies and gentlemen, good day and welcome to the Sun Pharmaceutical Q4 FY '13 Earnings Conference Call. As a reminder, for the duration of this conference, all participant lines will be in the listen-only mode. There will be an opportunity for you to ask questions at the end of today's presentation. Please note that this conference is being recorded.
I would now like to hand the conference over to Mr. Nimish Desai. Thank you, and over to you, sir.
Nimish Desai - IR: Thank you and good evening and warm welcome to our fourth quarter and FY '13 earnings call. I am Nimish from the Sun Pharma Investor Relations team. We understand that there is some delay in most of you getting our press release, but it will come to you shortly. This would also be shortly available on our website.
Let me introduce the Sun Pharma team today we have with us this evening Mr. Dilip Shanghvi, Managing Director; Mr. Sudhir Valia, Whole Time Director, and Mr. (Abhay Gandhi), President. Today they will discuss performance highlights, update on strategies and respond to any questions that you may have. As is usual, for the ease of discussion, we will look at the consolidated financials. Just as a reminder, this call is being recorded and a replay will be available for the next few days. The call transcript will also be put out on the website shortly.
The discussion today might include certain forward-looking statements and these must be viewed in conjunction with the risks that our business faces. I request you to restrict yourself to two questions. If you have more questions, I request that you rejoin the queue. I also request all of you to kindly send in your questions that may remain unanswered today.
I'll now hand over the call to Mr. Shanghvi. Over to you, sir.
Dilip Shanghvi - Managing Director: Thank you, Nimish. Welcome and thank you for joining us for this earnings call after the announcement of financial results for the fourth quarter of 2012-13. Our sales for financial year '13 have crossed $2 billion mark and it is interesting for us to note that it took us almost 27 years to reach turnover of $1 billion in terms of revenue. At this time, I am happy to point out that we crossed the next $1 billion in another three years. So, in a way, it's a reflection of the performance of the entire team at Sun Pharma.
Also, on occasion of our completing 30 years of operation, I am pleased to announce a reward for shareholders in terms of bonus shares of one share held for each share held by him.
Now, let me briefly update you on significant events during the year. As you know, earlier this year, we received U.S. FDA approval for generic liposomal doxorubicin injection. This reaffirms our strategy for building technological strength with complex products.
We also closed two important acquisitions in the year as we had shared with you; URL's generic business and DUSA. Both this strengthen our U.S. presence and we have begun to look at ways to grow this businesses.
As of March 2013, we had cash and cash equivalent of $1.3 billion. This periodically raises expectations from investors about acquisitions. I would like to once again repeat our strength. We will share more information when there is something to share. Until then all the expectations are near conjuncture.